Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jiang-Shan Tan has a total of 73 co-authors. Here are the top co-authors by number of shared publications:

  • Yuejin Yang

    Department of Cardiology State Key Laboratory of Cardiovascular Disease National Center for Cardiovascular Diseases Fuwai Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing People's Republic of China

    3 shared publications
  • Lu Hua

    Fuwai Shenzhen Hospital, Chinese Academy of Medical Sciences, Shenzhen, 518057, China; Key Laboratory of Pulmonary Vascular Medicine, Department of Cardiology, National Clinical Research Center of Cardiovascular Diseases, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, China

    2 shared publications
  • Mengjin Hu

    State Key Laboratory of Cardiovascular Disease, FuWai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100037, China

    2 shared publications
  • Qiujin Qian

    Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Peking University Sixth Hospital, Beijing, China

    2 shared publications
  • Song Hu

    Heart Failure Center, Department of Cardiology, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, National Clinical Research Center of Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100037 Beijing, China

    2 shared publications
  • Dejie Wang

    Ultrasound Department of Shandong Electric Power Central Hospital, Jinan, China

    1 shared publication

Latest Publications

  • Open Access

    Genetic Evidence Linking Lipoprotein(a) to Cardiovascular Disease and the Potential Role of Aspirin: A Mendelian Randomization Study

    by Jiangshan Tan, Wei Xu, Song Hu, Jingyang Wang, Lulu Wang, Jun Zhu, Yanmin Yang

    Background: Many studies have revealed the observational associations between lipoprotein(a) (Lp(a)) concentrations and the incidence of cardiovascular diseases (CVDs). However, the causal associations remain unclear. Methods: Public summary data were analyzed using a Mendelian randomization (MR) design to assess the causal associations between Lp(a) levels and risks of nine CVDs and evaluate the potential impact of aspirin on Lp(a) levels. The principal analysis was conducted employing the random-effects inverse-variance weighted (IVW) method. Furthermore, the weighted median and MR-Egger approaches were used as the sensitivity analysis. Additionally, the significantly associated single nucleotide polymorphisms (SNPs) in salicylic acid (INTERVAL and EPIC-Norfolk, n = 14,149) were chosen to assess the potential effects of aspirin on lowering Lp(a) levels. Results: The IVW analysis showed that the per standard deviation (SD) increment in Lp(a) level was causally associated with a higher risk of coronary artery disease (odds ratio (OR), 1.237; 95% confidence interval (CI), 1.173–1.303), atrial fibrillation (OR, 1.030; 95% CI, 1.011–1.050), heart failure (OR, 1.074; 95% CI, 1.053–1.096), hypertension (OR, 1.006; 95% CI, 1.004–1.008), and peripheral artery disease (OR, 1.001; 95% CI, 1.001–1.001) (all p < 0.001). The investigation did not reveal any significant heterogeneities or instances of horizontal pleiotropy. Furthermore, for each SD increase in salicylic acid concentration, there was a corresponding 5.4% reduction in Lp(a) levels (OR: 0.946, 95% CI: 0.900–0.993; p = 0.022). Conclusions: A causal nexus was discerned between Lp(a) levels and an increased risk of conditions including coronary artery disease, atrial fibrillation, heart failure, hypertension, and peripheral artery disease. Furthermore, administering aspirin may be a potential therapeutic to reduce these CVD risks among individuals with elevated Lp(a) levels.


  • Open Access

    Development and validation of a 10-year predictive model for cardiovascular and metabolic disease risk: insights from a large-scale health examination cohort

    by Dejie Wang, Jiang-Shan Tan, Ruihan Liu, Yingjuan Ma, Yugang Han, Wei Gan, Yanmin Yang, Jian Cao

    Objective: To develop and validate a 10-year predictive model for cardiovascular and metabolic disease (CVMD) risk using comprehensive health examination data from nearly 37 701 individuals. Methods: This retrospective cohort study used health examination data, including demographic information, clinical measurements, laboratory tests and lifestyle factors. Potential predictors were selected based on a literature review and exploratory analysis. Machine learning techniques (including random forest and gradient boosting) were employed to develop the predictive model. The model’s performance was evaluated using accuracy, sensitivity, specificity and area under the receiver operating characteristic curve (AUC). Model validation was conducted on separate test and validation sets. Results: A total of 37 701 electric power employees were included in this study after applying rigorous inclusion and exclusion criteria. The dataset was divided into training, validation and testing sets in a 70:15:15 ratio, with no significant differences observed in baseline characteristics, ensuring robust analysis. Feature selection using the random forest classifier identified the top predictors of CVMD. Machine learning models, particularly random forest and gradient boosting, demonstrated superior predictive performance compared with traditional Cox regression methods. These results significantly outperformed traditional Cox models, which yielded an AUC of approximately 0.60. Correlation analysis revealed strong associations between key variables, such as systolic and diastolic blood pressure, low-density lipoprotein and total cholesterol, and creatinine and blood urea nitrogen, highlighting the complex interactions among CVMD risk factors. Conclusion: The developed 10-year predictive model for CVMD risk, based on health examination data, shows promising potential for early identification and targeted intervention in individuals at high risk for CVMDs. This approach could contribute to the reduction of CVMD incidence and related morbidity and mortality.


  • Open Access

    Causal associations between telomere length and pulmonary arterial hypertension: A two-sample Mendelian randomization study

    by Ting-Ting Lyu, Jing-Yang Wang, Jiang-Shan Tan, Yan-Min Yang, Yi-Meng Bmed Wang, Jing Zhao, Ping Qing, Ling-Min Wu, Xiao-Jian Wang

    Pulmonary arterial hypertension (PAH) is a life-threatening condition characterized by elevated pulmonary artery pressure, leading to right heart failure, and mortality. The role of telomere length, a marker of biological aging, in PAH remains unclear. We utilized summary-level data from genome-wide association studies for various measures of telomere length and PAH. Single nucleotide polymorphisms associated with telomere length at a genome-wide significance level were used as instrumental variables. The inverse variance weighted method was the primary analysis, with sensitivity analyses including the weighted median and Mendelian randomization-Egger regression. The odds ratios and 95% confidence intervals (CI) were calculated to estimate the causal effect of telomere length on PAH risk. The Mendelian randomization analyses revealed no significant causal association between overall telomere length and PAH (odds ratios per standard deviation increase = 1.229, 95% CI: 0.469–3.222, P = .676). Similar null findings were observed for granulocyte, lymphocyte, naive T-cell, memory T-cell, B-cell, and natural killer-cell telomere lengths. Sensitivity analyses confirmed the robustness of the results, with no evidence of horizontal pleiotropy or significant influence of individual single nucleotide polymorphisms on the overall estimates. This Mendelian randomization study didn’t support a causal association between telomere length and PAH.

  • Open Access

    Exploring the association between COVID-19 and male genital cancer risk in European population: evidence from mendelian randomization analysis

    by Dejie Wang, Yingjuan Ma, Lin Yan, Wei Gan, Yugang Han, Jiang-Shan Tan, Wenhua Zhao

    Recently accumulated evidence indicates a potential association between COVID-19 and elevated susceptibility to cancer, including male genital cancer. However, the causal nature of this relationship remains unclear. In this Mendelian randomization (MR) study, we investigated the potential causal relationship between COVID-19 and male genital cancer using genetic variants as instrumental variables. We utilized summary statistics from two large-scale genome-wide association studies of COVID-19 hospitalized Vs. controls, as well as data from a population-based male genital cancer database based on European ancestry. We applied stringent quality control measures to select instrumental variables, including checking for linkage disequilibrium, removing low-quality variants, and assessing the strength of the instruments using the F-statistic. We conducted the MR analysis using the inverse-variance weighted method and several sensitivity analyses (including MR Egger and Weighted Median MR analysis) to test the robustness of our results. Our MR analysis revealed no causal associations between COVID-19 hospitalization and the incidence of male genital cancer. In the inverse-variance weighted analysis, no causal associations were observed between patients with COVID-19 hospitalization and the incidence of male genital cancer (odds ratio = 1.000 and 95% confidence interval = 0.998-1.001, p = 0.668). The estimated causal effect was consistent across all sensitivity analyses (including the Weighted Median, the MR Egger analysis, and the MR PROSSO analysis). The leave-one-out analysis showed that there was no any sing Single-nucleotide polymorphism significantly influencing our results. Our study provides evidence that there is no causal association between COVID-19 hospitalization and male genital cancer.


  • Open Access

    Roles of obesity in mediating the causal effect of attention-deficit/hyperactivity disorder on diabetes

    by Ningning Liu, Jiang-Shan Tan, Lu Liu, Haimei Li, Yufeng Wang, Yanmin Yang, Qiujin Qian

    Aims: Previous observational studies have reported potential associations among attention-deficit/hyperactivity disorder (ADHD), obesity, and diabetes (including type 1 and type 2 diabetes mellitus [T1DM/T2DM]). However, whether the association between ADHD and diabetes is mediated by obesity is unknown. Methods: With two-sample Mendelian randomization, we analysed the causal effect of ADHD on T1DM and T2DM and six obesity-related traits [including body mass index, waist circumference (WC), hip circumference, waist-to-hip ratio (WHR), body fat percentage and basal metabolic rate] and the causal effect of these obesity-related traits on T1DM/T2DM. Finally, with multivariable Mendelian randomization, we explored and quantified the possible mediation effects of obesity-related traits on the causal effect of ADHD on T1DM/T2DM. Results: Our results showed that ADHD increased the risk of T2DM by 14% [odds ratio (OR) = 1.140, 95% confidence interval (CI) = 1.005–1.293] but with no evidence of an effect on T1DM (OR = 0.916, 95% CI = 0.735–1.141, P = 0.433.). In addition, ADHD had a 6.1% increased causal effect on high WC (OR = 1.061, 95% CI = 1.024–1.099, P = 0.001) and an 8.2% increased causal effect on high WHR (OR = 1.082, 95% CI = 1.035–1.131, P = 0.001). In addition, a causal effect of genetically predicted high WC (OR = 1.870, 95% CI = 1.594–2.192, P < 0.001) on a higher risk of T2DM was found. In further analysis, WC mediated approximately 26.75% (95% CI = 24.20%–29.30%) of the causal association between ADHD and T2DM. Conclusions: WC mediates a substantial proportion of the causal effect of ADHD on the risk of T2DM, which indicated that the risk of T2DM induced by ADHD could be indirectly reduced by controlling WC as a main risk factor.


  • Open Access

    Left Atrial Diameter and the Risk of Thromboembolism in Patients with Left Ventricular Noncompaction

    by Wei Xu, Yanmin Yang, Jun Zhu, Jiangshan Tan, Jingyang Wang, Lulu Wang

    Aims: Patients with left ventricular noncompaction (LVNC) are at risk of thromboembolism. The relationship between left atrial diameter (LAD), a robust predictor for thrombosis, and LVNC is unclear. The purpose of this study was to explore the effect of LAD on the thrombotic risk in LVNC. Methods: In this retrospective cohort study, 320 patients with imaging characteristics of LVNC were included for statistical analysis. The primary endpoint was a composite event of intracardiac thrombi and stroke or transient ischemic attack (TIA). The secondary endpoints were intracardiac thrombi and stroke/TIA. Results: The 320 included patients (211 [65.9%] men, median age: 45 years [interquartile range: 30–57]) were divided into LAD1 (n = 157) and LAD2 (≥43 mm, n = 163) groups based on the median LAD. Throughout the median follow-up of 34 months, the incidence of thromboembolism among them was 7.2%: 11 (3.4%) patients had stroke/TIA and 14 (4.4%) had intracardiac thrombi. The rate of thromboembolism in the LAD2 group was higher than that of patients in the LAD1 group (11.0% vs. 3.2%, p = 0.007). Kaplan–Meier survival curves suggested that a LAD ≥ 43 mm was associated with a higher risk of thromboembolism and intracardiac thrombi (log-rank test, all p < 0.05). After adjusting for potential risk factors, LAD ≥ 43 mm was found to be an independent risk factor for thromboembolism (p = 0.013) and stroke (p = 0.024). The area under the receiver operating characteristic curve of LAD for predicting thromboembolism reached 0.696 at 1 year, 0.635 at 2 years, and 0.660 at 3 years. Conclusions: A larger LAD was related to a higher risk of thromboembolism in patients with LVNC. The LAD may be a useful predictor for thrombotic risk stratification among such patients.


  • Open Access

    Clinical and Safety Outcomes Associated with Extended Treatment of Venous Thromboembolism: A Network Meta-Analysis

    by Zhiqiang Liu, Jiangshan Tan, Yuanrui Deng, Lu Hua, Tingting Guo

    Background: Many anticoagulant strategies are available for the extended treatment of venous thromboembolism, yet little guidance exists regarding which drug is most effective and safe. Aim: A network meta-analysis was performed to resolve this uncertainty. Methods: We searched the medical literature through June 2022 for randomized controlled trials (RCTs) evaluating the efficacy and safety of anticoagulants for adults with VTE compared with other anticoagulants or a placebo. Results: We identified 13 eligible RCTs in 12 articles. All pooled hazard ratios (HR) and 95% credible intervals (CrI) mentioned below, except that for aspirin, were calculated by comparison with standard-intensity warfarin. Novel oral anticoagulants (NOACs) were not inferior to standard-intensity warfarin in preventing recurrence, and edoxaban was ranked first among the NOACs (HR, 0.99; 95% CrI, 0.70–1.39). All the NOACs, except rivaroxaban, were superior to standard-intensity warfarin in preventing bleeding events. Apixaban was ranked first and was considered to be safer than other NOACs for control of both major bleeding (HR = 0.07, 95% CrI: 0.01–0.37) and clinically relevant non-major bleeding (CRNMB, HR = 0.30, 95% CrI: 0.13–0.67). Edoxaban was ranked second among the NOACs for control of major bleeding (HR = 0.44, 95% CI: 0.21–0.88), and dabigatran was ranked second among the NOACs for control of CRNMB (HR = 0.54, 95% CrI: 0.4–0.73). Conclusions: There existed no statistically significant differences in recurrence between NOACs and standard-intensity warfarin, and NOACs were associated with a lower risk of bleeding events. Edoxaban effectively prevented VTE recurrence and major bleeding, and apixaban was the best anticoagulant for controlling bleeding events.


  • Open Access

    Corrigendum: Genetic predisposition between COVID-19 and four mental illnesses: A bidirectional, two-sample Mendelian randomization study

    by Ningning Liu, Jiang-Shan Tan, Lu Liu, Yufeng Wang, Lu Hua, Qiujin Qian

    Corrigendum: Genetic predisposition between COVID-19 and four mental illnesses: A bidirectional, two-sample Mendelian randomization study

  • Open Access

    Comparison of Six Different Percutaneous Coronary Intervention Guidance Modalities

    by Mengjin Hu, Jiangshan Tan, Yuejin Yang

    Background: New randomized trials and modalities in guiding percutaneous coronary intervention (PCI) have become available. Objective: We aimed to compare the clinical outcomes of coronary angiography (CAG), intravascular ultrasound (IVUS), optical coherence tomography (OCT), fractional flow reserve (FFR), instantaneous wave-free ratio (iFR), and optical frequency domain imaging (OFDI)-guided PCI. Methods: A network meta-analysis was performed to compare different PCI guidance modalities. The clinical outcomes included major adverse cardiovascular events (MACE), all-cause death, myocardial infarction (MI), and target vessel/lesion revascularization (TVR/TLR). Odds ratio (OR) and corresponding 95% credible interval (CrI) were calculated. Results: Thirty-six randomized trials, including 19,042 patients, were included. In comparison with CAG, IVUS significantly reduced MACE (OR: 0.71; 95% CrI: 0.57 to 0.86) and TVR/TLR (OR: 0.53; 95% CrI: 0.43 to 0.66). MACE (OR: 1.44; 95% CrI: 1.02 to 2.08) and TVR/TLR (OR: 1.87; 95% CrI: 1.04 to 3.71) were significantly increased in the FFR group, compared with IVUS group. There were no significant differences in MACE or TVR/TLR among the left guidance modality comparisons. Differences in all-cause death or MI were not observed in any comparisons. Conclusions: IVUS could reduce MACE and TVR/TLR, compared with CAG or FFR. Therefore, IVUS may be the optimal modality in guiding PCI.


  • Open Access

    Chronic Thromboembolic Pulmonary Hypertension in Females: Clinical Features and Survival

    by Yan Wu, Song Hu, Xin-Xin Yan, Fu-Hua Peng, Jiang-Shan Tan, Ting-Ting Guo, Xin Gao, Lu Hua

    Sparse data are available on the female-specific features of chronic thromboembolic pulmonary hypertension (CTEPH). We prospectively enrolled 160 consecutive female patients who were firstly diagnosed with CTEPH between 2013 and 2019 to explore their clinical phenotypes, treatment patterns, and long-term survival. The patients’ mean age was 54.7 ± 13.8 years, 70.6% provided a confirmed history of venous thromboembolism, 46 (28.8%) patients underwent pulmonary endarterectomy (PEA), 65 (40.6%) received balloon pulmonary angioplasty (BPA), and 49 (30.6%) were treated with medical therapy alone. The patients were followed for a median of 51 (34–70) months; three patients were lost to follow-up, and twenty-two patients died. The estimated survival rates at 1, 3, 5, and 7 years were 98.1% (95% CI 96.0–100), 96.9% (95% CI 94.2–99.6), 85.1% (95% CI 78.1–92.2), and 76.2% (95% CI 65.2–87.2), respectively. After adjusting for the confounders, the results of the multivariate Cox analysis showed that the presence of anemia (5.56, 95% CI 1.6–19.22) was associated with an increased risk of all-cause death, and compared with medical treatment, receiving PEA and BPA decreased the risk of death by 74% (0.26, 95% CI 0.07–0.97) and 86% (0.14, 95% CI 0.04–0.57), respectively. In conclusion, in the modern era of CTEPH treatment, invasive revascularization combined with targeted therapy display good clinical outcomes for females; anemia should be actively modified, which may lead to clinical improvements. (ClinicalTrials.gov Identifier: NCT05360992).